Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The criminals know that there could be an offering coming, and that they could easily manipulate it down from its days high, off of that most of the volume was day traders who would sell out if it rolled over,knowing that there wouldn't be many wanting to take it over night on concerns about an offering, so they turned their machines of criminal manipulation on and shorted it down, if there was any news of a cancelation of the possible offering,the scm bags and their shorting machines would get hit so hard,they wouldn't no what hit them,and blown them out squeezed into the ground.
we shall see, this is almost the identical beat down as DMK - these shares are coming from somewhere...
Yup, a lot of manipulation going on, really hope that a large portion of the volume is shorting, just so it adds to the next leg up, as they get their butts handed to them.
i am frankly amazed how much consolidation has gone in at mid 50's level.
Yea great point. Yo Yo.
Today's shorters better keep a pair of depends close by, if it was to take out $0.80,they will be in a big rush to put them on.
yep 50-70 what a freakin swinga
dropped again to .56 then popped again to .64
aka Y0~YO
You are the best Democrat
That’s why the Cowboys killed the Indians
WOW WHATTA SWINGER UP & DOWN 55-73 TO 54-78 NOW 65
As of August 8, 2023, there were 6,968,796 shares of common stock, par value $0.01 per share, outstandin
He who tells somebody to sell he’s trying to make the stock go up
BXRX$ Break On Through to the other side $1
BXRX$Enter Sandman Metallica, 20 million shares pre-market WOW!
Low on operating capital, which is commonplace with clinical trial drug discovery start ups
So they print more shares along with effecting reverse splits
Take the profit
He who sells and runs away lives to buy another day
Tra la
THEY GOT PLENTY OF OFFERS LOL https://dilutiontracker.com/app/search/BXRX
BXRX$ Cypress Hits On The Bong
As am I
Method to the madness
INSANE!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
MALVERN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (the “Company” or “Baudax Bio”) (NASDAQ: BXRX), a biotechnology company focused on developing T cell receptor (“TCR”) therapies utilizing human regulatory T cells (“Tregs”), as well as a portfolio of clinical stage Neuromuscular Blocking Agents (“NMBs”) and an associated reversal agent, today announced that U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its lead clinical candidate TI-168 for the treatment of Hemophilia A with inhibitors. TI-168 is the Company’s next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors.
“We are very pleased with the FDA’s decision to grant orphan drug designation to TI-168, which we believe highlights the urgent need for innovation and new therapeutic options for Hemophilia A patients,” said Gerri Henwood, President and Chief Executive Officer of Baudax Bio. “We believe this is an important therapeutic area, with established preclinical proof of concept in TI-168 through successes observed in Hemophilia A with inhibitors in animal models. With an Investigational New Drug (IND) application already FDA-cleared, we believe we can activate the Phase 1/2a Clinical Trial of TI-168 for Treatment of hemophilia A with inhibitors with a modest initial budget, and advance this therapy to further clinical investigation in early 2024.”
The FDA’s Office of Orphan Products Development grants orphan status to drugs being developed to treat, diagnose, or prevent a rare disease or condition affecting fewer than 200,000 people in the United States. Orphan Drug Designation is designed to provide drug developers with various benefits to support the development of novel drugs, including the potential for market exclusivity for seven years upon FDA approval, eligibility for tax credits for qualified clinical trials, waiver of application fees, reduced annual product fees, clinical protocol assistance and potential qualification for expedited development programs.
About Baudax Bio
Baudax Bio is a biotech company focused on innovative products for certain auto-immune conditions, of which many but not all, are orphan drug conditions as well as acute care and related settings. The combined company will further the development of Treg therapy specific to HA (pipeline candidate TI-168). TI-168 is a next-generation, FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitor. By combining the patented Treg culture method and TeraImmune designed FVIII-specific TCR, the Company has successfully demonstrated the therapeutic concept of FVIII TCR-Treg therapy in controlling of FVIII ADA in a hemophilic animal model. The lead program TI-168 has shown encouraging pre-clinical data and the FDA has cleared an IND to commence a Phase 1/2a clinical trial for the treatment of Hemophilia A with inhibitors.
$BXRX Case Study: Unique New Trading Strategy
One of our guys came up with a pretty cool trading strategy. He's doing really well with it.
Here's a video with the details:
#BXRX ?? huge gap fill play for 126% move! Can move next week? $BXRX
Had .50-.59’s, wow wee! Sold em all 1.30’s -1.20, just missed a 6 digit proft, oh well, lol $$$$$
Here's a BXRX celebration vid.
Sorry not 28K...38K
I'm holding if I start making some crazy money, I will share with you we will find a way to do that can't thank you enough. I'm up $28K
Good job! Most don't listen to my advice.
Bought at 0.60… went for a nice swim in Playa Del Carmen. Just got back and made 100% ??????
I WOULD BE A SELLER HERE !!
I'm making a small fortune right now.
Too many buy orders coming in $2.00-$3.00
Followers
|
22
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
356
|
Created
|
11/26/19
|
Type
|
Free
|
Moderators |
March 26, 2020 | 17.57M |
CHURCHILL WINSTON J | Director | Mar 26 | Buy | 2.28 | 6,500 | 14,820 | 6,500 | Mar 30 08:00 PM |
CHURCHILL WINSTON J | Director | Mar 26 | Buy | 2.44 | 25,000 | 61,000 | 52,782 | Mar 30 08:00 PM |
Weisman Wayne | Director | Mar 26 | Buy | 2.29 | 10,000 | 22,900 | 40,582 | Mar 27 03:53 PM |
ALTOMARI ALFRED | Director | Mar 26 | Buy | 2.34 | 5,000 | 11,700 | 33,382 | Mar 27 03:51 PM |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |